Invest Securities confirms its buy recommendation on Crossject shares, with a price target slightly reduced from 6.3 to 6 euros.

Yesterday, the company secured its financial horizon with the signature of a 12mE financing agreement in the form of OCAs amortizable over 3 years, reports the analyst, a transaction that will finance the industrial and commercial ramp-up of ZENEO.

The market has taken a dim view of the deal, due to its complexity and uncertainties over potential dilution. Nevertheless, it should remain relatively non-dilutive in view of ZEPIZURE's FDA approval and marketing in H2 24", the analyst believes.

Invest indicates that the 1st tranche of the financing will be reimbursed via the issue of new shares.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.